Literature DB >> 6889525

Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration.

F A Levi, W J Hrushesky, F Halberg, T R Langevin, E Haus, B J Kennedy.   

Abstract

Three hundred and forty-one female F344 (Fischer) rats were kept in light for 8 hr alternating with darkness for 16 hr; some were observed for survival for 21 days, while others were killed for blood sampling 4.5 days after a single intraperitoneal (i.p.) injection of 11 mg/kg cis-diamminedichloroplatinum (cis-DDP). cis-DDP was administered with or without concomitant i.p. saline load at one of six equispaced circadian stages. This high dose of cis-DDP resulted in marked lethal and renal toxicity, but in a moderate bone marrow suppression. Blood urea nitrogen (BUN), circulating total white blood cell counts (WBC) and survival times revealed statistically significant circadian rhythms of drug toxicity (P less than 0.03). Optimal tolerance for cis-DDP gauged by these three variables resulted from drug administration in the second half of the dark span. Renal tolerance for cis-DDP guaged by BUN was improved two-fold by appropriate drug timing. This benefit from drug timing alone was further improved two-fold if hydration and cis-DDP were given at the optimal circadian stage. Hydration-induced ameloriation of cis-DDP nephrotoxicity requires time qualification of both hydration and cis-DDP.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889525     DOI: 10.1016/0277-5379(82)90116-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  10 in total

1.  Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve.

Authors:  B Hecquet; M Sucche
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 2.  Circadian Rhythms, Disease and Chronotherapy.

Authors:  Yool Lee; Jeffrey M Field; Amita Sehgal
Journal:  J Biol Rhythms       Date:  2021-09-22       Impact factor: 3.649

3.  Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.

Authors:  Y Mizumura; Y Matsumura; T Hamaguchi; N Nishiyama; K Kataoka; T Kawaguchi; W J Hrushesky; F Moriyasu; T Kakizoe
Journal:  Jpn J Cancer Res       Date:  2001-03

4.  The circadian clock gene Bmal1 facilitates cisplatin-induced renal injury and hepatization.

Authors:  Min Zha; Ting Tian; Weilong Xu; Su Liu; Jia Jia; Lijuan Wang; Qianhua Yan; Nan Li; Jiangyi Yu; Liji Huang
Journal:  Cell Death Dis       Date:  2020-06-10       Impact factor: 8.469

5.  Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Frederic C Laquer; Larisa Y Poluektova; Jiangeng Huang; Yazen Alnouti; Masanao Yokohira; Lora L Arnold; Alexander V Kabanov; Samuel M Cohen; Tatiana K Bronich
Journal:  Int J Nanomedicine       Date:  2012-06-08

6.  Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.

Authors:  H Uchino; Y Matsumura; T Negishi; F Koizumi; T Hayashi; T Honda; N Nishiyama; K Kataoka; S Naito; T Kakizoe
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

7.  Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.

Authors:  Yoshihiro Seto; Fumiyasu Okazaki; Keiji Horikawa; Jing Zhang; Hitoshi Sasaki; Hideto To
Journal:  BMC Cancer       Date:  2016-09-27       Impact factor: 4.430

Review 8.  (Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity.

Authors:  Ž Večerić-Haler; A Cerar; M Perše
Journal:  Stem Cells Int       Date:  2017-12-12       Impact factor: 5.443

Review 9.  Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges.

Authors:  Martina Perše; Željka Večerić-Haler
Journal:  Biomed Res Int       Date:  2018-09-12       Impact factor: 3.411

10.  Pharmacokinetic evaluation and antitumor potency of liposomal nanoparticle encapsulated cisplatin targeted to CD24-positive cells in ovarian cancer.

Authors:  Keisuke Ashihara; Yoshito Terai; Tomohito Tanaka; Yoshimichi Tanaka; Satoe Fujiwara; Kazuya Maeda; Satoshi Tunetoh; Hiroshi Sasaki; Masami Hayashi; Masahide Ohmichi
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.